24.05.2012 - France Biotech has presented its 2011 biotech survey together with France Biotech. The results are very favorable for the country.
Paris – The data of the Life Science Panorama 2010/11 survey provided by Ernst & Young claim a leading role for French biotechnology in the world. The accounting specialist has found an impressive number of 1,359 life science companies that are active in France, ranking the country 2nd in the world in terms of the number of such companies. However, the survey gives no clear criteria for the selection of the firms included. Other studies use clearly defined and internationally comparable criteria defined by the OECD. Furthermore, Ernst & Young only surveyed only about 200 companies. 103 firms responded. On this basis, Ernst & Young calculated annual revenues of €261 million in France. In comparison, a report from biotechnologie.de conform to OECD criteria found 552 biotech companies in Germany with €2.4bn in sales. As in Europe, the amount of private equity available for biotechs dropped sharply in France between 2010 and 2011 from €460m to €277m according to Ernst & Young, while the number of start ups founded balanced the number of companies liquidated (24 versus 25). However, the lack of private money could be largely compensated by state programmes such as the FSI-PME programme. France also expanded its product pipeline. According to the report, 320 therapeutic products were in development whilst 20 were already being marketed in 2011. On top of that, diagnostic companies sold 59 in-vitro diagnostics and 21 in-vivo diagnostics.
According to the report, the first foreign acquisitions by French companies took place in 2011. Swedish Cellartis AB was bought by Paris-based Cellectis S.A. and SC World Inc. from Japan by Vivalis SA (Nantes). In return, two French companies were acquired by foreign enterprises, namely Novagali Pharma S.A. (Évry) by Santen Pharmaceutical Co. Ltd. (Japan) and Ipsogen SA (Marseille) by Qiagen N.V. (Netherlands).
27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.
JANUS® G3 Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 μl to 5000 μl for consistent and reproducible sample preparation more